Therapeutic | Duvortuxizumab |
Target 1 | CD19 |
Heavy Chain 1 | QVTLRESGPALVKPTQTLTLTCTFSGFSLSTSGMGVGWIRQPPGKALEWLAHIWWDDDKRYNPALKSRLTISKDTSKNQVFLTMTNMDPVDTATYYCARMELWSYYFDYWGQGTTVTVSS |
Light Chain 1 | ENVLTQSPATLSVTPGEKATITCRASQSVSYMHWYQQKPGQAPRLLIYDASNRASGVPSRFSGSGSGTDHTLTISSLEAEDAATYYCFQGSVYPFTFGQGTKLEIK |
100% seqID Fv 1 Structure | None |
99% seqID Fv 1 Structure | None |
95-98% seqID Fv 1 Structure | None |
Target 2 | CD3E |
Heavy Chain 2 | EVQLVESGGGLVQPGGSLRLSCAASGFTFSTYAMNWVRQAPGKGLEWVGRIRSKYNNYATYYADSVKGRFTISRDDSKNSLYLQMNSLKTEDTAVYYCVRHGNFGNSYVSWFAYWGQGTLVTVSS |
Light Chain 2 | QAVVTQEPSLTVSPGGTVTLTCRSSTGAVTTSNYANWVQQKPGQAPRGLIGGTNKRAPWTPARFSGSLLGGKAALTITGAQAEDEADYYCALWYSNLWVFGGGTKLTVL |
100% seqID Fv 2 Structure | None |
99% seqID Fv 2 Structure | None |
95-98% seqID Fv 2 Structure | None |
Follow these links to our prediction tools:
Format | Bispecific scFv with Crossover |
Isotype | na |
Highest Clinical Trial (Jan '20) | Phase-I |
Estimated Status (Jan '20) | Discontinued |
Recorded Developmental Technology | Dual-Affinity Re-Targeting Technology |
INN Year Proposed | 2016 |
INN Year Recommended | 2017 |
Companies Involved | Janssen Biotech, MacroGenics |
Conditions Approved | na |
Conditions Active | na |
Conditions Discontinued | Diffuse large B cell lymphoma, Follicular lymphoma, Non-Hodgkin's lymphoma, Precursor B-cell lymphoblastic leukaemia-lymphoma |
Notes |